# Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

> **NCT06238921** · PHASE1,PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 31 (estimated)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer

## Interventions

- **RADIATION:** Stereotactic Radiation
- **DRUG:** Zimberelimab
- **DRUG:** Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT06238921
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-19
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238921, "Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT06238921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*